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INVITED REVIEW
The menopause transition and women’s health at midlife: a progress
report from the Study of Women’s Health Across the Nation (SWAN)
Samar R. El Khoudary, PhD, MPH, FAHA,1 Gail Greendale, MD,2 Sybil L. Crawford, PhD,3
Nancy E. Avis, PhD,4 Maria M. Brooks, PhD,1 Rebecca C. Thurston, PhD,1,5,6
Carrie Karvonen-Gutierrez, PhD, MPH,7 L. Elaine Waetjen, MD,8 and Karen Matthews, PhD1,5,6
Abstract
Objective: Our initial understanding of the menopause transition (MT) has been framed by clinical samples of
women seeking treatment rather than by population-based studies. The Study of Women’s Health Across the Nation
(SWAN) initiated in 1996 with an overall goal to define the MT, to characterize its biological and psychosocial
antecedents and sequelae in an ethnically and racially diverse sample of midlife women.
Methods: This review summarizes the central findings of SWAN to date that can inform women and their
healthcare providers about the impact of the MT and midlife aging on overall health and well-being.
Results: SWAN characterized changes in reproductive axis and menstrual cycle patterns that informed the
development of the reproductive aging staging system Staging of Reproductive Aging Workshopþ10; MT-related
symptoms and mental health (vasomotor symptoms, sleep complaints, psychological symptoms, cognitive perfor-
mance, and urogenital and sexual health); and physiological systems and functions (cardiovascular and cardio-
metabolic health, bone health, physical function performance) that are influenced by the MT. SWAN demonstrated
substantial interrelations among these changes and significant racial/ethnic differences in the rate and magnitude of
change in multiple health indictors in midlife women. The findings point to midlife as a critical stage for adopting
healthy behavior and preventive strategies.
Conclusions: Over the past 23 years, SWAN has advanced our understanding of the impact of the MT and
midlife aging on health and well-being in women. SWAN will be instrumental to determine whether MT-related
changes during midlife are related to unfavorable health and well-being in early old age.
Key Words: Midlife – Menopause transition – Women – Aging – Symptoms.
T
he menopause transition (MT) is a major health
milestone for women with influences that extend
far beyond reproduction. In addition to the symptoms
that accompany menopause, concomitant biological, psycho-
logical, behavioral, and social changes shape women’s mid-
life and future health. Much of what we now know about the
MT, its characteristics, and its consequences is the product of
a series of seminal cohorts that were established in the 1980s
and 1990s.1-6 These longitudinal studies broadened our under-
standing of the MT, which was formerly based on reports of
women seeking clinical care and was not reflective of the
more general MT experience.
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Begun in 1996, the Study of Women’s Health Across the
Nation’s (SWAN’s) mission was to define the MT, to char-
acterize its biological and psychosocial antecedents and
sequelae, and to do so in an ethnically and racially diverse
sample of women (Black, Chinese, Hispanic, Japanese, and
White). The principal content areas in SWAN included the
reproductive axis; menstrual cycle characterization; MT-
related symptoms and mental health; sleep; bone health; body
composition; cardiovascular risk factors and outcomes; phys-
ical function and performance; cognitive performance; and
vaginal and urogenital health.
The goal of this article is to summarize central findings of
SWAN to date that can inform women and their healthcare
providers about the impact of the MT and midlife aging on
overall health and well-being. First, we provide an overview
of the design of the SWAN study including a description of
relevant ancillary studies. Next, we summarize SWAN con-
tributions to our understanding of changes in (1) reproductive
axis and menstrual cycle patterns that informed staging of the
MT; (2) symptoms and mental health; and (3) physiological
systems and functions that are influenced by the MT. In each
of these main areas, we provide, if known, how they are
different (or similar) in each of the SWAN’s racial/ethnic
groups. We provide the clinical and research implications of
the reviewed findings and conclude with the next steps
SWAN will take to understand women’s health in midlife
and early old age (defined as the time when adverse changes
in health and function start to accumulate7). To aid the use of
the reviewed information for clinical care, teaching, and/or
research, we include a ‘‘take home messages box’’ for each
topic area and provide a central illustration figure that sum-
marizes the impact of the MT and midlife aging on women’s
health and well-being.
OVERVIEW OF THE SWAN STUDY DESIGN
SWAN is a multisite, multiracial/ethnic, longitudinal
cohort study.6 Starting in 1996, SWAN enrolled 3,302 women
at seven geographically distinct sites across the United States:
Boston, MA; Chicago, IL; Pittsburgh, PA; Detroit, MI; Oak-
land, CA; Los Angeles, CA; Hudson County, NJ. The Coor-
dinating Center is located at the University of Pittsburgh and
the Central Laboratory is located at the University of Mich-
igan. At enrollment, women were between 42 and 52 years of
age, had an intact uterus and at least one ovary, were not
receiving hormone therapy, were not pregnant or lactating,
and had at least one menstrual period in the 3 prior months.
Each site enrolled Non-Hispanic White women and women
from one other predetermined racial/ethnic group. SWAN
enrolled White (n ¼ 1,550), Black (n ¼ 935), Japanese (n ¼
281), Chinese (n ¼ 250), and Hispanic (n ¼ 286) women.
Since enrollment, a baseline visit and 16 follow-up visits have
been conducted through 2017.
At each visit, SWAN participants completed a standard
protocol that included interview- and self-administered
questionnaires focused on menstrual bleeding patterns, clin-
ical health history, health behaviors, and psychosocial
factors; sexual health, assessment of anthropometric mea-
sures, physical performance, and cognitive function; and
provision of blood and urine samples. Self-administered
monthly calendars for recording ofmenstrual flow heaviness
as well as end-of-month questions on symptoms, gyneco-
logical surgery, and exogenous hormone use were collected
through the MT. Each clinical site also elected to collect
additional measures related to local scientific resources and
interest at selected evaluations. Thus, some sites assessed
body composition and bone density; radiographic knee
osteoarthritis; subclinical cardiovascular atherosclerosis;
and objective measures of sleep. At the most recent visit,
a subset of women at all sites participated in protocols of
accelerometer-assessed physical activity and measures of
vaginal health.
The annual assessments of menstrual bleeding patterns and
reproductive hormones—as well as monthly menstrual cal-
endars—were of particular importance to the SWAN design
because they allowed for precise identification of menopausal
stages and the timing of the final menstrual period (FMP).
SWAN defined the following stages: premenopausal (no
change in bleeding patterns); early perimenopause (change
in length of bleed or interbleed interval); late perimenopause
(no bleeding in 3-11 months); natural postmenopause (no
bleeding in 12 months not due to hysterectomy), surgical
menopause (bilateral oophorectomy with or without hyster-
ectomy), hysterectomy with one or two ovaries retained, and
hormone use before FMP. To disentangle the effects of MT
and chronological aging, analyses included measures of the
MT and aging into the same models to identify independent
effects. Because hormone use may mask the FMP, SWAN
took into account hormone use in models at the various MT
stages as well.
The depth and breadth of SWAN’s contribution to under-
standing the MT and midlife aging extend through several
existing sub- and ancillary studies. Of relevance to this report
are the Daily Hormone Substudy (DHS) and the SWAN
Sleep, the SWAN Mental Health, the SWAN Heart, and
the SWAN Cardiovascular Fat ancillary studies. The DHS
included a daily collection of first morning voided urine for an
entire menstrual cycle or up to 50 days (whichever comes
first) for 10 annual visits to characterize patterns of urinary
hormone metabolites throughout menstrual cycles over the
MT among a subset of SWAN participants (n ¼ 848) across
all clinical sites. The SWAN Sleep ancillary study collected
in-home polysomnography (PSG) and actigraphy measures of
sleep among a subset of SWAN participants (n ¼ 370) across
four clinical sites. The SWAN Mental Health ancillary study
measured lifetime psychiatric diagnoses at baseline and
occurrences of depression annually among SWAN partici-
pants from one site (n ¼ 443). The SWAN Heart ancillary
study measured subclinical markers of atherosclerosis over
two visits among participants from two SWAN sites (n¼ 608)
and the SWAN Cardiovascular Fat ancillary study quantified
volumes of cardiovascular heart fat depots among SWAN
Heart participants at one visit (n ¼ 564).
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WHAT WE HAVE LEARNED FROM SWAN
The reproductive axis, menstrual cycle patterns, and
stages of the MT
As one of the largest and longest studies of the MT, SWAN
has provided precise characterization of the main hormonal
alterations and menstrual cycle changes that accompany the
MT and define stages of reproductive aging (Box 1).8
The reproductive axis over the MT
Estradiol (E2) and follicle-stimulating hormones (FSHs)
changed dramatically over the MT. Overall, E2 decreased
across the FMP beginning at 2 years before the FMP and
continuing for 2 years after the FMP, with a stabilization
2 years after the FMP. On the contrary, FSH increases across
the MT with a gradual increase beginning 7 before the FMP
and continuing until approximately 2 years before the FMP,
followed by a remarkable increase in the time period of
2 years before to 2 years after the FMP, and finally a
stabilization 2 years after the FMP.9
Interestingly, the time course and pattern of these hormonal
changes across the MT did not vary by age at FMP or obesity,
and they were conserved across racial/ethnic groups.9 Instead,
the levels of circulating E2 and FSH varied by body mass
index (BMI) and race/ethnicity. Obesity markedly attenuated
the rise in FSH level after FMP and was negatively associated
with E2 level before FMP, but positively associated after
FMP. Race/ethnicity was not associated with the span of FSH
changes across the FMP, but Chinese and Japanese women
had a shorter span of E2 changes and a slightly lower E2 levels
than White or Black women.9
SWAN demonstrated for the first time that not all midlife
women experienced one pattern of E2 decline or FSH rise
over the MT.10 Among 31.5% of SWAN women, E2 rose
around 5.5 years before the FMP with a steep decline almost
1 year before the FMP. A similar rise of E2 was observed
among 13.1% of SWAN women, but with a slow decline over
2 years after the FMP. A third group of 26.9% experienced a
slow-decline pattern with no E2 rise before FMP, and a last
group of 28.6% followed a limited flat decline across FMP.10
For FSH rise, three patterns were observed across the MT,
with 40.7% of the evaluated participants followed a high FSH
rise, 48.7% amedium rise, and 10.6% followed a low rise FSH
pattern. Interestingly, the rise pattern of E2 before the FMP
was mainly observed among non-obese women of all racial/
ethnic groups, whereas the flat E2 and low rise FSH patterns
were more pronounced among obese women of all racial/
ethnic groups (Box 1).10
Menstrual cycle patterns
The menstrual calendar data showed that the menstrual
cycle length increased beginning 7.5 years before the FMP,
with the steepest increase starting 4 years pre-FMP, and
increased variability in cycle length beginning 2 years pre-
FMP.11 Consistent with this finding, analyses of the SWAN
DHS found cycle length increased primarily in cycles without
evidence of luteal activity (ELA, presumed ovulatory) as
determined by the Kassam algorithm,12 whereas the mean
cycle length in ELA cycles was highly stable over time at 27
to 29 days.13 In turn, the percentage of ELA cycles declined
from almost 100% 10 years pre-FMP to 88% 5 years later,
followed by a sharper decline to 23% in the last year pre-
FMP.13 Chinese and Japanese participants had consistently
longer cycle length than non-Hispanic Whites, as did women
with an older age at MT onset, but these factors did not modify
the time trends.11 Black and Hispanic women had consistently
lower percentages of ELA cycles (overall 73% and 66%,
respectively) than non-Hispanic Whites, Chinese, and Japa-
nese (81%-83%), with no racial/ethnic effect modification of
MT-related declines (Box 1).13
MT stages: timing, duration, and correlates
SWAN participated in the ReSTAGE Collaboration—with
the Melbourne Women’s Midlife Health Project, the Seattle
Midlife Women’s Health Study, and the Treloar data—which
investigated aspects of menstrual cycle regularity as potential
markers of the early and late MT stages, proposed in the first
Staging ofReproductiveAgingWorkshop (STRAW).14 Pooled
analyses of monthly menstrual calendar data suggested a
persistent difference in consecutive menstrual cycle length
of seven or more days as the optimal marker of entry into
early stage of the MT, as this predicted subsequent FMP, was
observed in a high proportion of women, and occurred before
other candidate markers.15 ReSTAGE recommended at least
Box 1 Take-home messages: the reproductive axis, menstrual cycle patterns,
and stages of the menopause transition
Reproductive axis
 Patterns of E2 decline and FSH rise during the menopause
transition are heterogeneous across women.
 Irrespective of race/ethnicity, a midlife rise in E2 before the final
menstrual period is most common in nonobese women, whereas
obese midlife women are more likely to experience a nonrise
E2 (a flat trajectory) and a low-rise FSH over the menopause
transition.
Menstrual cycle patterns
 Cycle length increases over the menopause transition, particularly
in the upper tail of the distribution and in cycles without
evidence of luteal activity.
 Almost a quarter of midlife women may experience an ovulatory
cycle in the last year prior to their final menstrual period.
 Chinese and Japanese experience longer menstrual cycles than
White women.
 Black and Hispanic women are less likely to experience ovulatory
cycles than White, Chinese, and Japanese women.
MT staging: timing, duration, and correlates
 Pooled analysis across multiple women’s health cohorts including
SWAN marked an early stage of the menopause transition by a
persistent 7þ day difference in consecutive cycles, and a late
stage of the menopause transition by 60þ days of amenorrhea.
 Smokers experience earlier menopause transition onset, shorter
menopause transition duration and earlier age at natural menopause.
 Black women experience a longer menopause transition duration
than White women, and women whose menopause transition onset
is earlier experience a longer menopause transition duration.
E2, estradiol; FSH, follicle-stimulating hormone; MT, menopause
transition; SWAN, Study of Women’s Health Across the Nation.
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60 days of amenorrhea as the marker of entry into late stage of
theMT,16 as both 60þ days and 90þ days—used bymany past
studies17—were similarly predictive of subsequent FMP, but
60þ days was observed in a higher proportion of women and is
a more straightforward indicator for women and clinicians.17
Using the above STRAW criteria of early and late stages of
the MT, analyses of menstrual calendar data showed that
women who smoked had both an earlier onset of the MT and a
shorter total MT duration (defined as time from the onset of
the early MT to the FMP). Total MT duration was longer in
those with earlier age at MT onset and in Black women.
Shorter premenopausal cycle length was linked to shorter MT
duration, consistent with faster follicle depletion, whereas
women with irregular—and perhaps longer—cycles in mid-
reproductive age had a longer early-stage duration.18 Median
age at natural menopause was 51.4 years in the cross-sectional
screener data from SWAN19 and slightly higher at 52.5 years
among longitudinal cohort participants.20 In multivariate
modeling, race/ethnicity was not independently associated
with age at natural menopause,20 whereas time-varying cur-
rent smoking—but not baseline smoking—was linked to an
earlier age at natural menopause (Box 1).20
Symptoms and mental health
Vasomotor symptoms
Up to 80% of SWAN women reported vasomotor symp-
toms (VMS), defined as hot flashes and night sweats occur-
ring during the past 2 weeks, at some point during the MT,
with the highest reporting occurring during the transition from
early to late perimenopause.21 In contrast to long-held beliefs
that VMS last only a few years, frequent VMS persisted for a
median of 7.4 years, with even longer durations for some
women.22 Analyses examining individual trajectories of VMS
over the MT found four trajectories, with women falling into
approximately equal proportions across four groups.23 An
early onset group of women had VMS early in the transition
that continued after the FMP, but then declined. A later onset
group had VMS peaking at the FMP and continuing, though
declining, into their postmenopausal years. A third group had
few or no VMS throughout the MT, and a fourth group of
women, which we dubbed the ‘‘super flashers,’’ started VMS
well before their FMP that continued well into the postmeno-
pause. These findings provide insight into different patterns of
VMS experienced by women.
SWAN’s diverse cohort has provided additional insight
into racial/ethnic differences in VMS. Black women had the
highest prevalence and longest duration of VMS, and were
most bothered by their VMS.21,22,24 Asian women had the
lowest VMS prevalence, whereas Hispanic and White women
fell between the Black and Asian groups. Women in lower
socioeconomic positions were more likely to have VMS,
independent of race/ethnicity.21
Several other demographic and psychological factors were
associatedwithVMS. Less education, smoking, greater depres-
sive symptoms, greater anxiety, and more symptom sensitivity
were all significantly related to greater subsequent reporting of
VMS.21Depressedmood and anxietywere also associatedwith
greater perceived bother of VMS, independent of VMS fre-
quency.24 Women with a history of childhood abuse or neglect
were more likely to report VMS over the MT.25
SWAN has elucidated and helped resolve a complex rela-
tion between VMS and body weight/adiposity. In SWAN,
higher adiposity was a risk factor for VMS early in the
transition,26 but this relation reversed after women became
postmenopausal, with greater adiposity associated with lower
VMS.27 A similar reversal by menopause stage was noted
between VMS and adipokines or inflammatory substances
released by body fat.28
Although the physiology of VMS is not fully understood,
reproductive hormones likely play an integral role. In serum
samples from the full SWAN cohort and urine samples from
the DHS, lower E2 (or estrone conjugates in the case of urine
samples) and higher FSH levels were associated with VMS
reporting, particularly in the setting of non-ELA cycles.29
Variants in genes that encode for estrogen receptor alpha and
enzymes involved in synthesis and conversion of estrogens
predicted greater likelihood of VMS (Box 2).30
Sleep
Sleep is a multidimensional concept. Major dimensions of
sleep include duration, continuity, timing, regularity, and
satisfaction, in addition to sleep disorders. Some theorists
include daytime sleepiness and napping as indicators of poor
nighttime sleep in their models. Sleep dimensions can be
assessed by self-report (questionnaire, interview, diary),
behavioral movement (actigraphy), and PSG (multichannel
physiological recordings, including electroencephalogram
[EEG]). Not surprisingly, different measures of the same
dimension do not yield the same results. Thus, it is necessary
to take a comprehensive approach to understand the impact of
the MT on sleep.
In the SWAN initial cross-sectional survey, late perimeno-
pause and natural postmenopausal women reported more sleep
difficulties than did premenopausal women, regardless of the
occurrence of VMS. Postmenopausal hormone therapy users
had similar rates of sleep difficulties to premenopausal
women.31 A longitudinal analysis of the first 7 years of SWAN
showed a similar pattern of MT for self-reported sleep distur-
bance, defined as trouble falling asleep, waking up several
times, and waking up earlier than planned at least three nights
weekly in the last 2 weeks, with several exceptions. Early
perimenopause was also associated with more sleep distur-
bance and hormone therapy use did not protect postmenopausal
women from sleep disturbance. Frequent reporting of VMS, E2
decline, and FSH rise were also associated with sleep difficul-
ties.32 Waking up several times at night showed the most
pronounced association with menopause stage.
Most studies of menopause and sleep complaints report
averages across women by menopausal stage, which does not
address whether a subset of women is especially vulnerable to
the development of sleep disturbance near the FMP. Using
group-based trajectory modeling, four different patterns of
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sleep complaint trajectories were apparent over the MT. Only
15% reported increasing sleep complaints with the MT;
specifically, waking up frequently around the time of the
FMP. The other groups showed stability over the transition or
a linear increase consistent with aging-related increases in
sleep problems not specific to the MT.33 Black and White
women were more likely to experience an increasing preva-
lence of waking up frequently around the FMP, relative to the
other racial/ethnic groups.
Sleep data gathered by PSG within the SWAN Sleep
ancillary study paint another picture. More rapid increases
in FSH in the 7 years before the sleep protocol was
associated with longer sleep time and more deep sleep,
but consistent with the self-reported sleep disturbance, less
favorable self-reported sleep quality.34 A spectral analysis
of non-rapid eye movement sleep showed that beta EEG
power, a measure of cognitive arousal, was greater in late
perimenopausal and postmenopausal women than in pre-
and early perimenopausal women, with hot flashes
explaining part of this relationship of cognitive arousal
with menopausal status.35
Race/ethnic differences in sleep characteristics and their
determinants are substantial. White women reported the most
sleep complaints and Hispanic women the fewest in the full
SWAN cohort.32 US-born Hispanic, Chinese, and Japanese
women had more sleep complaints compared to their first-
generation immigrant ethnic counterparts.36 On the contrary,
Black women had shorter sleep duration, longer sleep latency,
and lower sleep efficiency measured by PSG compared to both
White and Chinese women in the SWAN Sleep ancillary
study.37 In addition, EEG beta power was higher and delta
power lower in Black compared to White women. Actigraphy
measures of sleep in the SWAN cohort show similar results:
Black and Hispanic women had shorter sleep and lower sleep
efficiency thanWhitewomen.38Themajor factors thatmediated
race/ethnic differences in actigraphy were financial hardship
and increasing health problems, and for Black women, VMS.
The associations of sleep at midlife with health outcomes
have focused thus far primarily on cardiovascular health. In the
SWAN Sleep ancillary study, women who had the metabolic
syndrome had less PSG-assessed sleep efficiency, more beta
power, and greater apnea/hyponea scores (an indicator of sleep
disordered breathing), compared to those who did not.39
Women with multiple indicators of sleep disordered breathing
had elevated inflammatory and coagulation biomarkers.40 In
addition, Black women who had higher levels of C-reactive
protein also had shorter PSG sleep duration and those who had
higher levels of fibrinogen had lower sleep efficiency. Women
with lower total delta power showed increased diastolic blood
pressure over time.41 A delayed bedtime, relative to keeping
one’s usual bedtime,was related to increased insulin resistance,
but not to change in BMI over time (Box 2).42
Depressive symptoms and anxiety
A long-held belief is that women experience increased
depression and anxiety during the MT. Researchers continue
to evaluate the scientific evidence for this belief and whether
VMS, sleep disruption, and other stressful factors contribute
to negative moods at midlife.
SWAN has measured depressive symptoms using the Cen-
ter for Epidemiological Studies of Depression (CES-D) scale
at baseline and at all subsequent visits. At baseline, 23% of
SWAN women scored 16 or higher on the CES-D, the cut-
point for indicating potential clinical depression.43 In longi-
tudinal analyses,44 the odds of having high depressive symp-
toms were significantly greater in the early peri-, late peri-, or
postmenopause, as compared to the premenopause, with
Box 2 Take-home messages: symptoms and mental health
Vasomotor symptoms
 Up to 80% of midlife women experience vasomotor symptoms
during the menopause transition, with the patterns of vasomotor
symptoms heterogeneous across time.
 Vasomotor symptoms can last more than 8 years, with a longer
duration if experienced early in the transition.
 Black women have the highest prevalence, longest duration, and
are most bothered by their vasomotor symptoms, whereas Asian
women have the lowest vasomotor symptoms prevalence.
 Adiposity could be a risk factor for vasomotor symptoms early in
the transition but appears to be protective at later stages of the
menopause transition.
Sleep
 Self-reported sleep complaints increase across the menopause
transition.
 During midlife, sleep duration and deep sleep measured
objectively do not worsen and may improve.
 Black and Hispanic women have shorter sleep duration and less
efficient sleep relative to White women.
 Poor sleep may have an adverse impact on women’s cardiovascu-
lar health at midlife.
Depressive symptoms and anxiety
 Depressive symptoms and anxiety are somewhat higher during late
peri- and postmenopause than premenopause.
 Other factors such as stressful life events, financial strain, low
social support, sleep problems, and low physical activity are
important contributors to depressive symptoms and/or anxiety,
independent of the menopause transition.
 Of those examined in SWAN, testosterone is the only hormone
related to depressive symptoms.
 Black women are less likely to experience increases in depressive
symptoms, whereas Hispanic women are more likely to
consistently experience depressive symptoms over midlife.
Cognitive performance
 Menopause-related cognitive performance difficulties are characterized
by a temporary absence of learning during perimenopause that
resolves in postmenopause (when learning resumes).
 Age-related cognitive performance decline starts later after
menopause and is related to chronological age but not to time
since the final menstrual period.
Genitourinary and Sexual Health
 Decline in intercourse frequency does not lead to vaginal dryness
or pain with intercourse.
 Urinary Incontinence is a frequently reported symptom among midlife
women that is not related to menopause or estradiol decline.
 Sexual functioning declines become apparent 20 months before the
final menstrual period and slows after the final menstrual period.
 Compared to White, Black women show a smaller decline in
sexual function over the menopause transition, whereas Japanese
women show a larger decline.
SWAN, Study of Women’s Health Across the Nation.
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highest odds in the late perimenopause.43,44 However, stress-
ful life events, being Hispanic, and having low education
conveyed greater risk for high depressive symptoms than did
menopausal status.44 Testosterone was the only reproductive
hormone related to depressive symptoms and was positively
related to higher odds of depressive symptoms.44
Most studies of menopause and depression report mean
levels of depressive symptoms over the MT, which does not
address the heterogeneity of patterns of depressive symptoms
experienced by women. Using group-based trajectory model-
ing, five different trajectories of depressive symptoms over
midlife aging were identified. Half (50%) of the women had
very low CES-D scores (scores<5), 29% had scores less than
16 over the entire time, 11% of women initially had high CES-
D scores that decreased over time, and small groups of women
showed an increasing trend over time (5%) or consistently
high scores (5%) over time.45 Black women were less likely to
be in the increasing group and more likely to be in the
decreasing symptom trajectory. Hispanic women were more
likely to be in the consistently high group. The group with
increasing scores was characterized by lower physical activ-
ity, an increase in sleep problems, a smaller reduction in
stressful life events, and a decrease in social support. Baseline
menopausal status (ie, pre- or early perimenopausal) was not
associated with trajectory group membership.
In the SWAN Mental Health ancillary study, women were
two to four times as likely to experience a major depressive
episode in the MT or early postmenopause than in premeno-
pause,46 although menopause status was not a significant
predictor of first episode of major depression.47
Although anxiety symptoms are highly prevalent among
midlife women and may precede the onset of depressive
symptoms, they have received much less attention than
depression or depressive symptoms. SWAN has examined
anxiety longitudinally using a measure of anxiety based on a
composite of four anxiety symptoms: irritability, nervousness
or tension, feeling fearful for no reason, and heart pounding or
racing. Internal consistency of these items is good (Cronbach
alpha of 0.77) and the scores are highly correlated with the
Generalized Anxiety Disorder-7 (Spearman r ¼ 0.71), a
commonly used measure of anxiety. The odds of high anxiety
symptoms were significantly greater for early peri-, late peri-,
and postmenopause compared to premenopause, and peaked
in the late perimenopause.48 However, menopausal stage was
no longer significantly related to anxiety when analyses were
adjusted for frequent VMS. Among women who did not have
anxiety before the MT there was a greater likelihood of
reporting anxiety over the MT compared to when premeno-
pausal, independent of multiple risk factors, including upset-
ting life events, financial strain, fair/poor perceived health,
and VMS.48 Odds ratios for anxiety symptoms increased from
early peri- to late peri-, but then declined in postmenopause,
suggesting that increased levels of anxiety may be a tempo-
rary occurrence. Perceived health less than very good and at
least one upsetting event in the past year conveyed greater risk
of anxiety symptoms than did menopause stage (Box 2).
Cognitive performance
Approximately 60% of midlife women report problems
with memory during the MT, yet studies of measured cogni-
tive performance during the transition are rare.49-52 To
address unanswered questions about midlife cognitive func-
tion, the SWAN protocol included in-person serial tests of
cognitive processing speed, verbal episodic memory, and
working memory. SWAN’s initial, 4-year longitudinal anal-
ysis of the relation between the MT and cognitive perfor-
mance disclosed a temporary decrement in both processing
speed and verbal episodic memory during the perimenopause;
the decrement resolved in postmenopause.51 The negative
perimenopause effect was subtle, manifest as the absence of a
learning effect, meaning that cognitive test scores did not get
better with repeated administrations. Improvement with
repeated testing is normative in this age range.53 But even
in perimenopause, test scores did not drop—they simply did
not improve during this MT stage. It is important to make the
distinction between not getting better and an actual decline,
which was observed in a later analysis (see below).
It appears intuitive that symptoms associated with the MT,
specifically VMS, depressive symptoms, anxiety, and sleep
disturbance symptoms, would contribute to the cognitive
difficulties observed during perimenopause,54-56 but a subse-
quent, 6-year, longitudinal analysis from SWAN evaluating a
direct relation between these four MT symptoms and cogni-
tive performance did not uphold this thesis.52 There was no
association between cognitive performance and either VMS
or poor sleep, but women with depressive symptoms did score
lower in the domain of cognitive processing speed and those
with more anxiety symptoms had worse verbal episodic
memory. When all four symptoms were added to the models
of MT stage and cognition, the negative effect of late peri-
menopause on cognitive performance was unaltered, suggest-
ing that the presence of these symptoms does not account for
the perimenopause learning decrement.52
As the SWAN cohort aged and continued to undergo serial
waves of cognitive tests, age-related cognitive decline (also
known as cognitive aging) studies have been undertaken.
Age-related cognitive decline is a decline in cognitive perfor-
mance that can be a normal part of aging.57 There is
debate about whether age-related cognitive decline starts in
midlife.58
To circumvent the practice effects related to the initial two
testing occasions, age-related cognitive decline evaluation
started at the third cognitive assessment; starting after practice
effects have abated, one can observe an actual decline in
cognitive performance (if present).58
At analysis outset, the median age was 54 and 60% had
reached menopause. Cognitive processing speed and verbal
episodic memory declined with time, adjusted for MT stage,
MT symptoms, diabetes, race/ethnicity, education, and attri-
tion, consistent with age-related cognitive decline. To con-
sider whether the menopause, apart from chronological aging,
influenced cognitive decline, an alternate analysis strategy
was used, gauging cognitive performance as a function of
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time before and after the FMP. The decline in cognitive
processing speed and verbal memory per year of chronologi-
cal age was almost identical to the average, between-women
difference in cognitive processing speed by age at time of
FMP, supporting the thesis that the declines in cognitive
performance are not related to menopause, but rather, are a
function of chronological aging (Box 2).
Genitourinary and Sexual Health
Vulvovaginal symptoms
In longitudinal analyses, vaginal dryness increased across
the MT, from about 19% in pre- and early perimenopause to
34% in postmenopause years. Furthermore, vaginal dryness
contributed to pain during sexual intercourse.59 Advancing
menopausal stage was more strongly associated with vaginal
dryness than E2 decline, confirming a more complex etiology
of this symptom than low E2 levels alone. Naturally post-
menopausal women were less likely to develop vaginal
dryness than surgically menopausal women.59 Contrary to
popular belief that reduced intercourse frequency leads to
poorer vaginal function, reduced intercourse frequency did
not precede the development of vaginal dryness or pain
with intercourse.59 Importantly, sexual lubricant use was
associated with better sexual functioning scores around the
FMP and reduced the likelihood of developing sexual pain
(Box 2).59,60
Urinary incontinence
About 68% of SWAN women reported monthly or more
frequent urinary incontinence (UI; assessed as number of
times a participant had leaked urine, even a small amount
during the month before each annual visit) symptoms at least
once over the first 9 years of follow-up.61 Although SWAN
women who were continent at baseline had higher odds of
reporting new onset monthly or less frequent UI in early and
late perimenopause, women who were incontinent at baseline
actually reported greater improvement in their UI symptoms
during this same time frame, that is, mild UI symptoms were
just as likely to resolve as develop. Importantly, women in
early and late perimenopause were not more likely to develop
weekly or more frequent UI or experience worsening UI
symptoms than before or after the MT.62,63 Neither UI
development nor worsening was associated with E2 level
or change in E2 levels over time.64 Instead, aging, being
overweight, weight gain, and incident diabetes increased the
risk of developing UI and having weekly or more frequent UI
symptoms.62-64
Less than 40% of incontinent women sought treatment for
UI from a healthcare provider. Treatment seeking was most
strongly related to longer duration and greater frequency of UI
symptoms and was not associated with race/ethnicity, educa-
tion level, or socioeconomic status.61 Women with frequent
UI who did not seek treatment were more likely to report
inaccurate beliefs about UI (eg, UI is normal consequence of
aging) or motivational barriers (eg, provider never asked
about UI) as reasons for not seeking treatment (Box 2).65
Sexual functioning
Sexual functioning is an important component of women’s
lives with 75% of SWAN women at baseline reporting sex as
moderately to extremely important.66 Pain during sexual
intercourse increased and sexual desire decreased over the
MT, independent of sociodemographic characteristics, or
changes in health and psychological functioning.67 However,
menopausal stage was not associated with frequency of
sexual intercourse, emotional satisfaction with partner, or
physical pleasure, although vaginal dryness was an important
factor for all in adjusted analyses. Longitudinal data
showed that concurrent E2 level was not related to any
measured sexual function domain, but concurrent testosterone
level was positively associated with sexual desire, arousal,
and masturbation.68
SWAN has also conducted analysis of sexual function
relative to the FMP.60 Using a composite measure of sexual
functioning among naturally menopausal women who
remained sexually active throughout the MT, a decline in
sexual functioning became apparent 20 months before the
FMP and slowed 1 year after the FMP through 5 years
afterwards. This decline was not explained by factors such
as poorer health, VMS, vaginal dryness, depression, or
partner status.
Sexual functioning in midlife varied by race/ethnicity.
Compared to White women, Chinese and Japanese women
reported lower importance of sex, desire, masturbation,
arousal, and more sexual pain, whereas Black women
reported greater importance of sex, higher sexual intercourse
frequency, but more sexual pain, less arousal, less emotional
satisfaction, and less physical pleasure.67,69 Sexually active
Black women also had a smaller decline, whereas Japanese
women had a larger decline in sexual functioning across the
MT (Box 2).60
Physiological systems and functions
Cardiovascular and cardiometabolic health
Over the past 25 years, our understanding of whether and
how the MT could influence women’s cardiovascular disease
(CVD) risk has significantly evolved. Menopause is now
listed as a female-specific CVD risk factor per the American
Heart Association,70 and has been recognized as a risk-
enhancing factor favoring statin therapy initiation in the
2018 updated guidelines of blood cholesterol management
(Box 3).71
Traditional and novel CVD risk factors
By following women over the MT, SWAN documented
sharp increases in total cholesterol, low-density lipoprotein
cholesterol (LDL-C) and apolipoprotein (Apo)B levels within
a 1-year interval surrounding the FMP.72 Importantly, the
menopause-related acceleration in LDL-C was associated
with greater risk of carotid plaque later in life in a follow-
up analysis.73 Conversely, high-density lipoprotein choles-
terol (HDL-C) and ApoA did not decline over the MT.72 In
fact, a SWAN analysis by menopausal stage showed HDL-C
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to be the highest during the late peri- and early postmenopause
stages.74 Analysis from the SWAN Heart ancillary study
suggested potential changes in HDL quality over the MT,
with increases in HDL-C associated with less carotid intima
medial thickness (IMT) before, but with greater carotid IMT
after the FMP.75 Recent preliminary work showed that the
ability of HDL particles to promote cholesterol efflux capac-
ity, the main function by which HDL removes cholesterol
from peripheral cells, was reduced over the MT.76 Unlike
lipids, changes in blood pressure, insulin, glucose, and BMI
during midlife were not associated with the MT, independent
of chronological aging.72,77,78 However, the odds of develop-
ing metabolic syndrome were the highest during the perimen-
opause independent of age.79 Moreover, SWAN found a
relation between body composition, fat distribution, and
the MT.80-82 Using dual energy x-ray absorptiometry, SWAN
examined change in body composition, beginning 9 years
before and concluding 9 years after the FMP.80 About 2 years
before the FMP, the rate of fat gain doubled and lean mass
started to decline. Fat gains and lean losses continued until
2 years after the FMP and then flattened. Weight increased
linearly during the MT, but also plateaued 2 years after the
FMP.80 Black and White women had similar patterns of
change in body composition and weight in relation to the
FMP. Japanese women lost some lean mass during the MT
but, unlike White and Black women, did not gain fat mass.
Uniquely, Chinese women gained lean mass and lost fat mass
after menopause.80
Menopause-related fat distribution extended to other critical
locations that are relevant to cardiovascular health. In SWAN
Cardiovascular Fat ancillary study, postmenopausal women had
greater volumes of heart fat within and outside the pericardial
sac,81with the latter fat, knownas paracardial fat, associatedwith
greater risk of coronary artery calcification in postmenopausal
than premenopausal women.82 The proximity of heart fat to the
myocardium and the vasculature may result in a higher pro-
atherogenic contribution for this fat compared to other fat
depots.83 Heart fat has been associated with worse CVD risk
factors and a greater risk of CVD events.84
VMS, the hallmark of menopause, were associated with a
more adverse CVD risk factor profile, independent of age or
sex hormones. Reporting of VMS over the course of the MT
was associated with higher LDL-C, Apo B, triglycerides,85
and insulin-resistance,86 and with a greater risk for incident
hypertension (Box 3).87
Subclinical vascular health
SWAN reported detrimental changes to vascular health
over theMT. In SWANHeart ancillary study, yearly increases
in carotid IMT and interadventitial diameters, markers of
carotid atherosclerosis and remodeling, accelerated during
the late perimenopause stage independent of age.88 Additional
work from SWAN Heart ancillary study showed that metrics
of vascular function also were compromised over the MT.
Women who transitioned over a mean of 2.4 years of follow-
up experienced greater progression in aortic pulse wave
velocity, a marker of arterial stiffness, than women who
remained premenopausal or those who were postmenopausal
at baseline.89
Further work showed that changes in E2 and FSH might
contribute to vascular remodeling over the MT. Lower levels
of E2 and higher levels of FSH were associated with a wider
adventitial diameter or a thicker IMT over time independent
of age.90 When considering patterns of E2 and FSH changes
over the MT91; women who experienced a rise in E2 5 years
pre-FMP with an early decline at 1 year pre-FMP had lower
risk of carotid plaque after menopause than women with a flat
E2 decline trajectory. Furthermore, women with a lower FSH
rise over the MT had thinner IMT postmenopause.91
Similar to being adversely associated with traditional CVD
risk factors (described above), VMS might be a marker of
adverse underlying vascular changes.Women with hot flashes
had a lower flow-mediated dilation and a greater aortic
calcification independent of CVD risk factors and E2.92
Moreover, reporting more frequent VMS was associated with
thicker IMT.93 The timing of VMS across the MT might be
relevant for midlife vascular health according to a recent work
Box 3 Take-home messages: physiological systems and functions
Cardiovascular and cardiometabolic health
 Women experience adverse changes in their lipids, body fat
distribution, metabolic syndrome risk, and vascular health over
the menopause transition.
 Increases in LDL-C around the final menstrual period are
associated with greater risk of plaque presence after menopause,
but higher levels of HDL-C may not consistently be protective.
 Menopause transition-related fat redistribution extended to other
critical locations that are relevant to cardiovascular health.
 Sex hormones and greater vasomotor symptoms appear to be
related to adverse changes in cardiovascular health with risk
varying by patterns of E2 and vasomotor symptoms over the
menopause transition.
Bone health
 Bone mineral density loss starts a few years before the final menstrual
period, that is, during the menopause transition, not after menopause.
 Due to confounding by body size, Japanese and Chinese women
have lower bone mineral density than do White women, despite
having lower fracture rates, but composite strength indices
(estimated bone strength relative to demand) are better in
Japanese and Chinese than in White women.
 Non-White women in SWAN experience less decline in composite
strength indices in the 5 years before through the 5 years after
the final menstrual period.
Physical functioning
 Although physical functioning limitations are prevalent among
midlife women they are not necessarily a persistent problem.
 The menopause transition is associated with poor self-reported
physical function that is related to declines in E2 and T levels
over the menopause transition.
 Symptomatic changes experienced by menopausal women includ-
ing vasomotor symptoms, poor sleep, and perceived stress may
negatively affect physical functioning status.
 Physiologic changes across several body systems (eg, inflammation,
hemostasis, adipokines) during the menopause transition may under-
lie the observed changes in physical functioning during this time.
E2, estradiol; HDL-C, high-density lipoprotein cholesterol; LDL-C,
low-density lipoprotein cholesterol; SWAN, Study of Women’s
Health Across the Nation; T, testosterone.
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from SWAN.94 Women with early-onset VMS had thicker
IMT after menopause, independent of demographics and
CVD risk factors (Box 3).94
Bone mineral density, bone strength indices, and fractures
Although bone loss has long been considered a hallmark of
menopause, before SWAN, longitudinal examinations of how
bone mineral density (BMD) changed in relation to the MT
were scarce. In 1992, a landmark study of 75 US White
women illustrated that the term ‘‘post-menopausal bone loss’’
was misleading: BMD loss started a few years before the
FMP, that is, during the MT, not after menopause.95 SWAN
solidified and generalized this finding by quantifying changes
in spine and femoral neck BMD in relation to time before and
after the FMP in more than 2,000 Black, Chinese, Japanese,
and White women; in each group, BMD loss began 1 year
before the FMP and decelerated, but did not cease, 2 years
after it.96
Other results offered insight into the biology underlying
this temporal pattern of MT-related bone loss: 2 years
before the FMP, a sharp decline in serum E2 was accompa-
nied by a marked increase in urinary N-telopeptide (a bone
turnover marker), suggesting that a drop in E2 is one of
the triggers of the greater-bone-turnover-greater-bone-loss
cascade.97,98 Approximately 1.5 years after the FMP, urinary
N-telopeptide levels stabilized and serum E2 reached its nadir
level, presaging the lesser rate of BMD loss that commences
at about 2 years post-FMP.
In predominantly cortical bone, bone loss is characterized
by endosteal (inner surface) resorption and compensatory
periosteal (outer surface) formation, which increases the bone
diameter.99 SWAN showed that this cortical bone remodeling
also began 1 year before the FMP.100 However, gain in bone
diameter did not counterbalance the BMD loss, resulting in a
0.7% average annual decline in femoral neck strength (esti-
mated using composite strength indices, which quantify bone
strength relative to loading demand).100,101
Racial/ethnic variation in osteoporotic fracture risk is
recognized—for example, fracture rates among US Black
and Asian women are approximately half those of White
women —but our comprehension of the biology underlying
the fracture differential remains limited.102 Moreover, in
some instances, between-group differences in BMD do not
parallel between-group fracture risks; for example, average
BMDs of Japanese and Chinese women are lower thanWhite
women’s. SWAN baseline, cross-sectional analyses docu-
mented the paradoxical differences in BMD between its
Asian and White participants.103 But BMD alone is insuffi-
cient to capture fracture risk.104 Composite indices of femo-
ral neck strength, which forecast fracture risk in older adults,
combine BMD, femoral neck width, body height, and weight
to estimate bone strength relative to the demand experienced
during a fall from standing height. These indices help remove
the confounding of BMDby body size and bone size, which is
a particular problem in crossracial/ethnic BMD compari-
sons.101 On average, baseline composite strength indices
were greater in Chinese and Japanese compared to White
women, concordant with ethnic/racial differences in fracture
risk.105 Baseline values of composite strength indices pre-
dicted incident fracture during 9 years of follow-up. Race/
ethnicity predicted incident fracture independent of BMD,
but did not predict fracture independent of composite
strength estimates.106
Longitudinal analysis of change in composite indices in
relation to FMP-time disclosed a possible etiology of lesser
fracture risk in Asian and Black women compared to White
women.100 On average, at the end of the 10-year interval
bracketing the FMP (5 years prior through 5 years after it),
values of the composite strength indices were less in White
women than those of each of the three non-White subgroups
(Box 3).100
Physical functioning
Limitations in physical functioning have been widely
studied among older adults, but data from SWAN has been
instrumental in characterizing the midlife as a critical window
for the onset of poor physical functioning. In a cross-sectional
analysis of SWAN screening data, almost one-fifth of the
participants reported either moderate or substantial limita-
tions using the SF-36 physical functioning questionnaire.107
When considering the federal gait speed standard requirement
for safely crossing a pedestrian intersection (<1.22m/s) as a
benchmark for physical functioning mobility concerns, an
analysis among SWAN women from the Michigan site
showed that a surprisingly high percent of women, 31%
(mean age 47 years), had mobility issues that may affect
their pedestrian safety.108
Although physical functioning limitations are prevalent
among midlife women, findings from SWAN demonstrated
that they are not necessarily a persistent issue across time. In a
prospective analysis of five biennial measures of physical
functioning, only one-third of women never reported physical
functioning limitations, whereas 42% and 26% of women
reported ever experiencing some and substantial limitations,
respectively.109 On average, the probability of improving in
functioning was greater than the probability of worsening and
older age and high levels of economic strain were found to be
predictive of greater worsening.109
Changes in endogenous sex hormones during the MT,
including greater reductions in E2 and testosterone were
predictive of poorer physical functioning in SWAN
women.110 The burden of physical functioning limitations
differs by menopausal stage. Late perimenopause, postmen-
opause, or surgical menopause women reported poorer
levels of physical functioning111,112 as compared to pre-
menopausal women, adjusted for age. With respect to the
impact of symptoms on physical functioning, women
experiencing greater burden of VMS, urine leakage, poor
sleep, and perceived stress had poorer physical function-
ing.112 Thus, the physiologic and symptomatic changes
experienced by menopausal women may negatively affect
physical functioning status.
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The rapid physiologic changes occurring across several
body systems during the MT may underlie the observed
changes in physical functioning during this time. In site-
specific analyses, the systemic inflammatory biomarker, C-
reactive protein, was associated with poor self-reported phys-
ical functioning113 and high levels of leptin, a proinflamma-
tory adipokine, predicted poor performance on mobility-
related tasks.114 Inflammation was associated with poor
physical functioning in SWAN study-wide analyses as well;
adverse levels of C-reactive protein and hemostatic markers
including plasminogen-activator inhibitor 1, tissue plasmino-
gen activator antigen, and factor VIIc predicted poor perfor-
mance-based outcomes of physical functioning.115
Physical functioning is hypothesized to be not only an
outcome of adverse health factors during the midlife, but as a
marker of poor health. Women with poor self-reported physi-
cal functioning were at greater risk for metabolic syndrome116
and those with low grip strength had greater risk for diabe-
tes.117 Poor physical functioning may also be a marker of
early cardiovascular risk; walking speed was inversely asso-
ciated with carotid adventitial diameter among SWAN
women, a finding that was independent of traditional cardio-
vascular risk factors.118 It is likely that the relationships
between health behaviors, health outcomes, and physical
functioning are bidirectional, and so longitudinal studies such
as SWAN are critical to our understanding of the complexities
of these processes (Box 3).
CLINICAL IMPLICATIONS AND NEXT STEPS
Since its beginning in 1996, SWAN has made wide-ranging
contributions to women’s health and well-being at midlife.
SWAN has elaborated on the biological, symptomatic, and
psychosocial changes that accompany the MT, and character-
ized the health sequelae of the MT. SWAN findings empha-
size the diversity of the MT experiences among women,
especially those of different racial/ethnic backgrounds, and
underscore the multifactorial nature of the MT as a landmark
event in women’s lives. In addition, the findings point to
midlife as a critical stage for adopting healthy behavior and
preventive strategies.
SWAN’s characterization of the MT was instrumental to
the development of the criterion standard staging system,
STRAWþ10, which characterizes the stages of reproductive
aging. Use of such a standardized reproductive aging staging
system is critical to improving comparability across studies
of midlife and menopause and providing uniform clinical
terminology. SWAN findings underscore the heterogeneity
of the endocrinologic and symptomatic experience of the
MT as defined by patterns and timing of changes in sex
hormones, VMS, and sleep complaints. The heterogeneous
patterns of changes in E2 and VMS over the MT in SWAN
were associated with differences in cardiovascular health
outcomes after menopause, supporting the role of these
factors in cardiovascular risk stratification. The between-
women heterogeneity documented by SWAN underscores
the appropriateness of implementing a personalized
approach in both research and clinical practice when evalu-
ating MT health sequelae or designing MT-related thera-
peutic or behavioral interventions.
SWAN’s strong design and the breadth of information
collected over approximately two decades of follow-up time
enabled SWAN to unravel the contribution of the MT versus
midlife aging in several physiological systems and health
domains (Fig. 1; Central Illustration Figure: blue bars
depicting changes that were more driven by midlife aging
while light orange bars depicting changes that were more
driven by the MT). The adverse changes observed in markers
of cardiovascular (eg, lipids, vascular remodeling, body fat
deposition) and musculoskeletal (eg, bone density and physi-
cal function) health during midlife were more influenced by
the MT, whereas increases in blood pressure and BMI were
more influenced by midlife aging. Transient rise in cognitive
difficulties occurring during perimenopause, decline in sexual
functioning due to increased pain and decreased sexual desire,
and increases in sleep complaints and vaginal dryness were
more driven by the MT. Although women reported greater
depressive and anxiety symptoms during the MT, those
symptoms were transient and more impacted by stressful life
events, sleep problems, and low physical activity than theMT.
The reported findings from SWAN along with those of
other studies focusing on midlife1-5 point strongly to midlife
as a window of opportunity for maintaining or establishing
positive health behaviors to delay or prevent poor health
outcomes or disability later in life (Fig. 1). For example,
smoking cessation, healthy diet, and regular physical activity
are three important modifiable factors that can significantly
reduce cardiovascular risk.119 SWAN documented extremely
low prevalence of each of these modifiable factors with only
1.7% of the women evidencing positive healthy behaviors
over time.120 These findings call for more effort to educate
women about MT-related acceleration in their cardiovascular
risk and the importance of implementing a heart-healthy
lifestyle to reduce risk of CVD in later life.
Similar to cardiovascular health, the midlife is a critical
stage for musculoskeletal health. The decline in dual energy
x-ray absorptiometry-assessed BMD starts several years
before the FMP. This finding again points to the potential
for early intervention, including lifestyle modification along
with possibly prophylactic therapeutics that may delay and/or
reduce the burden of osteoporosis and fracture risk later in
life. Being physically active was associated with greater peak
femoral neck strength relative to load in pre- and early
perimenopausal women.121 SWAN also showed serum 25-
hydroxyvitamin D level below 20 ng/mL, which is partially
determined by diet, was associated with 85% hazard for
nontraumatic fracture development.122
The burden of physical functioning limitations among
SWANwomen also call for identifying ways in which women
can improve midlife physical functioning. Health behaviors
and the prevention of certain health conditions may be key
targets for potential interventions given their association with
midlife physical functioning. SWANwomen who had a better
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diet quality123 as well as an overall healthier lifestyle,124 and
particularly more physical activity125 had better midlife phys-
ical functioning. Furthermore, women free from health con-
ditions that commonly onset during the midlife, including
depressive symptoms, vision impairment, knee osteoarthritis,
and peripheral nerve impairment, have better functioning than
women afflicted with these conditions.126-129
Taken together, adopting healthy lifestyle behaviors is
critical to midlife women who face several changes in their
physical and psychological well-being, many of which are
highly related to the MT. Although this article has reviewed
findings by distinct scientific areas, it is essential to point out
that these domains are interrelated. For example, changes in
sex hormones have been linked to changes in cardiovascular
FIG. 1. Central Illustration Figure. The Contribution of the Menopause Transition and Midlife Aging to Women’s Health and Well-being: What Have
We Learned from the Study ofWomen’s Health Across the Nation (SWAN)?; SWAN contributed to our understanding of the impacts of the menopause
transition versus midlife aging on women’s health and well-being in different domains. The figure lists changes occurring during the menopause
transition that were reviewed in this paper, and differentiates whether these changes were more driven by the menopause transition or midlife aging
using different color schemes. Light orange bars depict changes that were mostly driven by the menopause transition, whereas blue bars depict changes
that were mostly driven bymidlife aging. Transient changes are identified when applicable by fading color bars and listing the word ‘‘Transient’’ at the
end of relevant bars. SWAN has identified midlife as a critical stage for adopting healthy behavior and preventive strategies.
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and physical functioning health.81,90,91,110 Both cardiovascu-
lar health and physical functioning are tightly linked and
SWAN demonstrated their interconnection.116,118 Sleep and
VMS symptomatology are interconnected and both have been
linked to cardiometabolic health.39,41,85,94 It is critical to
understand the impact of symptomatology changes on physi-
ologic changes as well as how changes within a body system
might impact changes in another system. Such knowledge will
elucidate mechanistic pathways of how midlife and the MT
might impact disease development and the aging process.
The MT experience of midlife women is strongly influ-
enced by their racial/ethnic background. SWAN has docu-
mented significant racial/ethnic differences in the rate and
magnitude of change in multiple health indictors, including
patterns and timing of sex hormones changes and VMS
reporting, declines in BMD, body composition, sleep char-
acteristics, depressive symptoms, and sexual health. The
reported racial/ethnic differences at midlife may drive the
widening of health disparities later in life; a hypothesis that
should be tested in future studies. It is critical that clinicians
and researchers realize the diversity in endocrinologic, symp-
tomatic, and physiologic changes of the MT among women of
different racial/ethnic backgrounds and how might this diver-
sity impact women future risk of disease and disability as well
as their therapeutic and prevention options.
Important limitations of the SWAN study included the
limited sample size of Hispanic participants which may
reduce ability to detect significant differences in MT char-
acteristics and its correlates among this ethnic group; recruit-
ing women aged 42 to 52 years old (mean age 47 years old) at
baseline making SWAN unable to study early menopause and
its sequels; and limited generalizability to geographical loca-
tions not included in the study, for example, southeast.
Next steps
SWAN has advanced our understanding of the impact of
the MT on health and well-being in midlife women. Whether
the MT-related changes during midlife set the stage for poor
health and well-being in early old age or represent a tempo-
rary set of physical and mental challenges is not known.
Owing to its long duration, SWAN participants have now
reached early old age. Therefore, SWAN now has the oppor-
tunity to examine the relation between prospectively charac-
terized MT and midlife health measures and later life health
and functional outcomes. This previously unavailable link
between the MT, midlife, and older age will allow identifica-
tion of interventions that may optimally preserve health and
function as women age.
CONCLUSION
Over the past 23 years, SWAN has advanced our under-
standing of the impact of the MT and midlife aging on
health and well-being in women. SWAN will be instru-
mental to determine whether MT-related changes during
midlife are related to unfavorable health and well-being in
early old age.
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